ClinicalTrials.gov
ClinicalTrials.gov Menu

Alternate-Day Buprenorphine Administration. Phase II - 4

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000222
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : June 24, 2005
Sponsor:
Collaborator:
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Study Completion Date : No date given
Publications:
Amass, bickel, Crean, Blake, Higgins (in press). Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology. Amass, Bickel, Crean, Blake, Higgins. (in press) Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology